Details of Disease

General Information of Disease (ID: DIS35WVW)

• Disease Name: Primary cutaneous T-cell lymphoma
• Disease Hierarchy:
  DISSXRTQ: T-cell lymphoma
  DISY0E8H: Primary cutaneous lymphoma
  DIS35WVW: Primary cutaneous T-cell lymphoma
• Disease Identifiers:
  MONDO ID: MONDO_0015758
  MESH ID: D016410
  UMLS CUI: C0079773
  MedGen ID: 36336
  HPO ID: HP:0012192
  Orphanet ID: 171901
  SNOMED CT ID: 1162973007

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 29 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Alclometasone	DMAE84F	Approved	Small molecular drug	[1]
Amcinonide	DMM1JL9	Approved	Small molecular drug	[2]
Betamethasone	DMAHJEF	Approved	Small molecular drug	[3]
Bexarotene	DMOBIKY	Approved	Small molecular drug	[4]
Clocortolone	DM9ZMQH	Approved	Small molecular drug	[5]
Cortisone Acetate	DMG8K57	Approved	Small molecular drug	[6]
Denileukin diftitox	DMMHR1U	Approved	NA	[7]
Desonide	DMTP2NJ	Approved	Small molecular drug	[8]
Desoximetasone	DM4PXF6	Approved	Small molecular drug	[9]
Dexamethasone	DMMWZET	Approved	Small molecular drug	[10]
Diflorasone	DMI9PRJ	Approved	Small molecular drug	[11]
Flumethasone	DMUNG4A	Approved	NA	[12]
Fluocinolone Acetonide	DMG2KI4	Approved	Small molecular drug	[13]
Fluocinonide	DM65KL8	Approved	Small molecular drug	[14]
Flurandrenolide	DMHCI9S	Approved	Small molecular drug	[15]
Fluticasone propionate	DMRWLB2	Approved	NA	[16]
Halcinonide	DMGLAX1	Approved	Small molecular drug	[17]
Hydrocortisone	DMGEMB7	Approved	Small molecular drug	[18]
Mechlorethamine	DM0CVXA	Approved	Small molecular drug	[19]
Methoxsalen	DME8FZ9	Approved	Small molecular drug	[20]
Methylprednisolone	DM4BDON	Approved	Small molecular drug	[21]
Mometasone	DM45OJN	Approved	Small molecular drug	[22]
Panobinostat	DM58WKG	Approved	Small molecular drug	[23]
Prednicarbate	DMBUNVW	Approved	Small molecular drug	[24]
Prednisolone	DMQ8FR2	Approved	Small molecular drug	[25]
Prednisone	DM2HG4X	Approved	Small molecular drug	[26]
Romidepsin	DMT5GNL	Approved	Small molecular drug	[27]
Triamcinolone	DM98IXF	Approved	Small molecular drug	[28]
Vorinostat	DMWMPD4	Approved	Small molecular drug	[29]

This Disease is Treated as An Indication in 2 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
IDP-122	DM3A701	Phase 3	NA	[30]
PDX-101	DM6OC53	Phase 2	Small molecular drug	[31]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 49 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CCR4	TT7HQD0	Limited	Biomarker	[32]
CD22	TTM6QSK	Limited	Biomarker	[33]
CD5	TTEGYK1	Limited	Altered Expression	[34]
CTLA4	TTI2S1D	Limited	Altered Expression	[35]
EPHA4	TTG84D3	Limited	Biomarker	[36]
HDAC7	TTMUEK1	Limited	Biomarker	[37]
HDAC9	TT8M4E1	Limited	Biomarker	[38]
IL31RA	TT9HPX0	Limited	Biomarker	[39]
KIR2DS2	TTV3CFI	Limited	Biomarker	[40]
SELPLG	TTS5K8U	Limited	Biomarker	[41]
BLK	TTNDSC3	Disputed	Altered Expression	[42]
ITGB7	TTLT9XQ	Disputed	Altered Expression	[43]
USP2	TTUEQ1W	Disputed	Altered Expression	[44]
KIR3DL2	TTQH3N0	moderate	Biomarker	[45]
ANG	TTURHFP	Strong	Altered Expression	[46]
ATM	TTKBM7V	Strong	Biomarker	[47]
BAX	TTQ57WJ	Strong	Biomarker	[48]
BRAF	TT0EOB8	Strong	Biomarker	[47]
CBL	TT7QT13	Strong	Altered Expression	[49]
CCL20	TT2XAZY	Strong	Biomarker	[50]
CCR3	TTD3XFU	Strong	Altered Expression	[51]
CCR6	TTFDB30	Strong	Genetic Variation	[52]
CD28	TTQ13FT	Strong	Genetic Variation	[53]
CTDSP1	TTHZAF0	Strong	Biomarker	[54]
DNMT3A	TTJUALD	Strong	Biomarker	[47]
FAS	TT7LTUJ	Strong	Biomarker	[55]
FKBP4	TTHY0FT	Strong	Biomarker	[56]
HDAC1	TT6R7JZ	Strong	Biomarker	[57]
IL16	TTW4R0B	Strong	Biomarker	[58]
IL17F	TT2B6PS	Strong	Biomarker	[59]
IL5	TTPREZD	Strong	Altered Expression	[60]
ITGAM	TTB69FJ	Strong	Biomarker	[61]
ITGB2	TTIJWR7	Strong	Biomarker	[61]
JAK1	TT6DM01	Strong	Biomarker	[62]
JAK3	TTT7PJU	Strong	Biomarker	[63]
MCL1	TTL53M6	Strong	Altered Expression	[64]
NFKB2	TTKLNRV	Strong	Biomarker	[47]
PLCG1	TT6T4JI	Strong	Altered Expression	[65]
PRKCQ	TT1MS7X	Strong	Biomarker	[47]
PTPN6	TT369M5	Strong	Biomarker	[66]
RARA	TTW38KT	Strong	Biomarker	[67]
RHOA	TTP2U16	Strong	Biomarker	[47]
SATB1	TTLFRIC	Strong	Altered Expression	[68]
TNFAIP3	TT5W0IO	Strong	Biomarker	[47]
TRB	TT84HCW	Strong	Biomarker	[69]
TRBC1	TT1DHW2	Strong	Biomarker	[69]
HDAC8	TTT6LFV	Definitive	Biomarker	[70]
IL3RA	TTENHJ0	Definitive	Biomarker	[71]
TDO2	TTXNCBV	Definitive	Altered Expression	[72]

This Disease Is Related to 62 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ARC	OTN2QQPG	Limited	Altered Expression	[73]
ASCC2	OT3B204T	Limited	Genetic Variation	[74]
BCL7A	OTYFUJTP	Limited	Posttranslational Modification	[75]
CCL26	OT2B7HR9	Limited	Altered Expression	[76]
CHFR	OTRAD2TT	Limited	Biomarker	[75]
FCRL3	OTIFXFWL	Limited	Altered Expression	[77]
FLG	OTE9QDV6	Limited	Altered Expression	[78]
GNG8	OT9YHSF1	Limited	Genetic Variation	[79]
GTF2H4	OTPD1DIU	Limited	Biomarker	[80]
GTSF1	OTV7PQJF	Limited	Altered Expression	[81]
HM13	OTGEO1LP	Limited	Biomarker	[54]
ICAM3	OTTZ5A5D	Limited	Altered Expression	[82]
IL22RA1	OTGVKLBR	Limited	Biomarker	[83]
NFKBIZ	OTU728KS	Limited	Altered Expression	[84]
OAS3	OT6E5FYS	Limited	Genetic Variation	[74]
PCM1	OTFM133C	Limited	Genetic Variation	[85]
PLS3	OTYBM4PK	Limited	Altered Expression	[86]
PTPRG	OT9N2WOF	Limited	Posttranslational Modification	[75]
RELB	OTU3QYEF	Limited	Biomarker	[80]
SART3	OTC1AM7S	Limited	Genetic Variation	[74]
SDC4	OTKUVUGZ	Limited	Altered Expression	[87]
STAT2	OTO9G2RZ	Limited	Biomarker	[88]
STK17B	OT4NYNO8	Limited	Biomarker	[40]
THBS4	OTA1T9KK	Limited	Posttranslational Modification	[75]
CARMIL2	OTV5S1J2	Disputed	Genetic Variation	[89]
IL2RG	OTRZ3OMY	Disputed	Altered Expression	[90]
NCOA1	OTLIUJQD	Disputed	Biomarker	[91]
NLN	OTFRITPU	Disputed	Biomarker	[92]
OPN4	OT1LZ7TS	Disputed	Biomarker	[92]
PREX1	OTUTPVA9	Disputed	Biomarker	[93]
TIGAR	OTR7NMRJ	Disputed	Altered Expression	[94]
LBH	OT87AT1X	moderate	Biomarker	[95]
AHI1	OT8K2YWY	Strong	Altered Expression	[96]
ARID1A	OTRWDV3P	Strong	Biomarker	[47]
BIN1	OTK8O0X8	Strong	Biomarker	[97]
CARD11	OTRCTLYC	Strong	Biomarker	[47]
CCR10	OT7ZWSSD	Strong	Altered Expression	[51]
CD164	OTZ7FIU8	Strong	Altered Expression	[98]
CTAGE1	OTWM7KSJ	Strong	Altered Expression	[81]
CTCF	OT8ZB70U	Strong	Biomarker	[47]
DNER	OT2GH2E5	Strong	Altered Expression	[99]
ERVW-1	OTWV8DXJ	Strong	Altered Expression	[100]
IRF4	OT1DHQ1P	Strong	Altered Expression	[101]
JUNB	OTG2JXV5	Strong	Altered Expression	[102]
LAIR2	OTKCADXC	Strong	Biomarker	[103]
MIA2	OTOGTUTU	Strong	Biomarker	[104]
NAV3	OT97M1TR	Strong	Biomarker	[105]
POT1	OTNBXJCQ	Strong	Genetic Variation	[106]
RAD23B	OT0PGOG3	Strong	Biomarker	[107]
SAMHD1	OTBCIBC7	Strong	Biomarker	[108]
SCPEP1	OT43LYEZ	Strong	Biomarker	[54]
SYCP1	OTWFV4KA	Strong	Biomarker	[54]
THEMIS	OTXODBXJ	Strong	Biomarker	[109]
TOX	OTE8BL5Z	Strong	Biomarker	[110]
TSPYL2	OTGGW2EF	Strong	Genetic Variation	[111]
APOA5	OTEVKLVA	Definitive	Genetic Variation	[112]
BCL11B	OT8KKCVJ	Definitive	Biomarker	[113]
CXCL17	OTRCEVIZ	Definitive	Altered Expression	[114]
DROSHA	OTCE68KZ	Definitive	Altered Expression	[115]
PDCD11	OTS1NJK2	Definitive	Biomarker	[116]
PPP1R11	OTSHYPPW	Definitive	Biomarker	[117]
SUPT7L	OTZJCPN1	Definitive	Biomarker	[59]

References

• [1] Alclometasone FDA Label
• [2] Amcinonide FDA Label
• [3] Betamethasone FDA Label
• [4] Bexarotene FDA Label
• [5] Clocortolone FDA Label
• [6] Cortisone acetate FDA Label
• [7] Advanced-stage primary cutaneous T-cell lymphoma treated with bexarotene and denileukin diftitox. Case Rep Dermatol. 2011 Jan;3(1):13-7.
• [8] Desonide FDA Label
• [9] Desoximetasone FDA Label
• [10] Dexamethasone FDA Label
• [11] Diflorasone FDA Label
• [12] Flumethasone FDA Label
• [13] Fluocinolone acetonide FDA Label
• [14] Fluocinonide FDA Label
• [15] Flurandrenolide FDA Label
• [16] Fluticasone propionate FDA Label
• [17] Halcinonide FDA Label
• [18] Hydrocortisone FDA Label
• [19] Mechlorethamine FDA Label
• [20] Methoxsalen FDA Label
• [21] Methylprednisolone FDA Label
• [22] Mometasone FDA Label
• [23] Panobinostat FDA Label
• [24] Prednicarbate FDA Label
• [25] Prednisolone FDA Label
• [26] Prednisone FDA Label
• [27] Romidepsin FDA Label
• [28] Triamcinolone FDA Label
• [29] Vorinostat FDA Label
• [30] A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
• [31] Belinostat FDA Label
• [32] C-C chemokine receptor 4 expression in CD8+ cutaneous T-cell lymphomas and lymphoproliferative disorders, and its implications for diagnosis and treatment.Histopathology. 2020 Jan;76(2):222-232. doi: 10.1111/his.13960. Epub 2019 Nov 13.
• [33] Ectopic expression of a novel CD22 splice-variant regulates survival and proliferation in malignant T cells from cutaneous T cell lymphoma (CTCL) patients.Oncotarget. 2015 Jun 10;6(16):14374-84. doi: 10.18632/oncotarget.3720.
• [34] Subtypes of cutaneous T-cell lymphoma defined by expression of leu-1 and Ia.Blood. 1982 May;59(5):876-82.
• [35] Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile.Cancer Immunol Res. 2018 Aug;6(8):900-909. doi: 10.1158/2326-6066.CIR-17-0270. Epub 2018 Jun 12.
• [36] Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in Szary syndrome identified by gene expression analysis.Cancer Res. 2004 Aug 15;64(16):5578-86. doi: 10.1158/0008-5472.CAN-04-1253.
• [37] Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism.Blood. 2009 Apr 23;113(17):4038-48. doi: 10.1182/blood-2008-08-176024. Epub 2008 Dec 12.
• [38] Synergistic Effect of Simvastatin and Romidepsin on Gamma-globin Gene Induction.Cell J. 2019 Jan;20(4):576-583. doi: 10.22074/cellj.2019.5589. Epub 2018 Aug 1.
• [39] A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1.J Allergy Clin Immunol. 2014 Feb;133(2):448-60. doi: 10.1016/j.jaci.2013.10.048. Epub 2013 Dec 25.
• [40] Identification of selectively expressed genes and antigens in CTCL.Exp Dermatol. 2008 Apr;17(4):324-34. doi: 10.1111/j.1600-0625.2007.00637.x. Epub 2007 Nov 2.
• [41] Circulating clonal CLA(+) and CD4(+) T cells in Sezary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7.Br J Dermatol. 2005 Feb;152(2):258-64. doi: 10.1111/j.1365-2133.2004.06325.x.
• [42] A novel BLK-induced tumor model.Tumour Biol. 2017 Jul;39(7):1010428317714196. doi: 10.1177/1010428317714196.
• [43] Retinoids Bias Integrin Expression and Function in Cutaneous T-Cell Lymphoma.J Invest Dermatol. 2015 Aug;135(8):2102-2108. doi: 10.1038/jid.2015.122. Epub 2015 May 7.
• [44] Ubiquitin-specific protease 2 decreases p53-dependent apoptosis in cutaneous T-cell lymphoma.Oncotarget. 2016 Jul 26;7(30):48391-48400. doi: 10.18632/oncotarget.10268.
• [45] From Natural Killer Cell Receptor Discovery to Characterization of Natural Killer Cell Defects in Primary Immunodeficiencies.Front Immunol. 2019 Jul 24;10:1757. doi: 10.3389/fimmu.2019.01757. eCollection 2019.
• [46] Increased HMGB1 levels in lesional skin and sera in patients with cutaneous T-cell lymphoma.Eur J Dermatol. 2018 Oct 1;28(5):621-627. doi: 10.1684/ejd.2018.3400.
• [47] Genomic landscape of cutaneous T cell lymphoma.Nat Genet. 2015 Sep;47(9):1011-9. doi: 10.1038/ng.3356. Epub 2015 Jul 20.
• [48] Expression of apoptosis regulators in cutaneous T-cell lymphoma (CTCL) cells.J Pathol. 2003 Jun;200(2):249-54. doi: 10.1002/path.1341.
• [49] c-CBL E3 Ubiquitin Ligase Expression Increases Across the Spectrum of Benign and Malignant T-Cell Skin Diseases.Am J Dermatopathol. 2017 Oct;39(10):731-737. doi: 10.1097/DAD.0000000000000780.
• [50] Disruption of CCL20-CCR6 interaction inhibits metastasis of advanced cutaneous T-cell lymphoma.Oncotarget. 2016 Mar 22;7(12):13563-74. doi: 10.18632/oncotarget.6916.
• [51] Expression of CCR3 and CCR4 Suggests a Poor Prognosis in Mycosis Fungoides and Szary Syndrome.Acta Derm Venereol. 2019 Jul 1;99(9):809-812. doi: 10.2340/00015555-3207.
• [52] Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.Oncotarget. 2017 Jan 31;8(5):7572-7585. doi: 10.18632/oncotarget.13810.
• [53] Functional analysis of acquired CD28 mutations identified in cutaneous T cell lymphoma.Cell Immunol. 2017 Sep;319:28-34. doi: 10.1016/j.cellimm.2017.07.002. Epub 2017 Jul 10.
• [54] Expression of cancer/testis antigens in cutaneous T cell lymphomas.Int J Cancer. 2002 Feb 10;97(5):668-70. doi: 10.1002/ijc.1643.
• [55] Epigenetically Enhanced PDT Induces Significantly Higher Levels of Multiple Extrinsic Pathway Apoptotic Factors than Standard PDT, Resulting in Greater Extrinsic and Overall Apoptosis of Cutaneous T-cell Lymphoma.Photochem Photobiol. 2018 Sep;94(5):1058-1065. doi: 10.1111/php.12925. Epub 2018 May 20.
• [56] Expression of FK506-binding protein 51 (FKBP51) in Mycosis fungoides.J Eur Acad Dermatol Venereol. 2018 May;32(5):735-744. doi: 10.1111/jdv.14614. Epub 2017 Nov 9.
• [57] Mass spectrometry and DigiWest technology emphasize protein acetylation profile from Quisinostat-treated HuT78 CTCL cell line.J Proteomics. 2018 Sep 15;187:126-143. doi: 10.1016/j.jprot.2018.07.003. Epub 2018 Jul 18.
• [58] Regulation of cellular processes by interleukin-16 in homeostasis and cancer.J Cell Physiol. 2014 Feb;229(2):139-47. doi: 10.1002/jcp.24441.
• [59] Oncogenomic analysis identifies novel biomarkers for tumor stage mycosis fungoides.Medicine (Baltimore). 2018 May;97(21):e10871. doi: 10.1097/MD.0000000000010871.
• [60] Expression of interleukin-18 and caspase-1 in cutaneous T-cell lymphoma.Clin Cancer Res. 2006 Jan 15;12(2):376-82. doi: 10.1158/1078-0432.CCR-05-1777.
• [61] Th17 cytokine differentiation and loss of plasticity after SOCS1 inactivation in a cutaneous T-cell lymphoma.Oncotarget. 2016 Jun 7;7(23):34201-16. doi: 10.18632/oncotarget.9077.
• [62] Psoralen with ultraviolet A-induced apoptosis of cutaneous lymphoma cell lines is augmented by type I interferons via the JAK1-STAT1 pathway.Photodermatol Photoimmunol Photomed. 2017 May;33(3):164-171. doi: 10.1111/phpp.12302. Epub 2017 Apr 17.
• [63] Partial trisomy 21 contributes to T-cell malignancies induced by JAK3-activating mutations in murine models.Blood Adv. 2018 Jul 10;2(13):1616-1627. doi: 10.1182/bloodadvances.2018016089.
• [64] Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1.Cancer Sci. 2009 Feb;100(2):341-8. doi: 10.1111/j.1349-7006.2008.01038.x.
• [65] Advanced-stage mycosis fungoides: role of the signal transducer and activator of transcription 3, nuclear factor-B and nuclear factor of activated T cells pathways.Br J Dermatol. 2020 Jan;182(1):147-155. doi: 10.1111/bjd.18098. Epub 2019 Jul 25.
• [66] Loss of SHP-1 tyrosine phosphatase expression correlates with the advanced stages of cutaneous T-cell lymphoma.Hum Pathol. 2007 Mar;38(3):462-7. doi: 10.1016/j.humpath.2006.09.012. Epub 2007 Jan 19.
• [67] Retinoic acid receptor alpha drives cell cycle progression and is associated with increased sensitivity to retinoids in T-cell lymphoma.Oncotarget. 2017 Apr 18;8(16):26245-26255. doi: 10.18632/oncotarget.15441.
• [68] SATB1 in Malignant T Cells.J Invest Dermatol. 2018 Aug;138(8):1805-1815. doi: 10.1016/j.jid.2018.03.1526. Epub 2018 May 8.
• [69] Absence of TCR loci chromosomal translocations in cutaneous T-cell lymphomas.Cancer Genet. 2011 Jul;204(7):405-9. doi: 10.1016/j.cancergen.2011.05.004.
• [70] Synthesis and Investigation of Therapeutic Potential of Isoform-Specific HDAC8 Inhibitors for the Treatment of Cutaneous T Cell Lymphoma.Anticancer Agents Med Chem. 2019;19(7):916-934. doi: 10.2174/1871520619666190301150254.
• [71] Utility of CD123 immunohistochemistry in differentiating lupus erythematosus from cutaneous T cell lymphoma.Histopathology. 2019 May;74(6):908-916. doi: 10.1111/his.13817. Epub 2019 Mar 20.
• [72] Biological and clinical significance of tryptophan-catabolizing enzymes in cutaneous T-cell lymphomas.Oncoimmunology. 2017 Feb 10;6(3):e1273310. doi: 10.1080/2162402X.2016.1273310. eCollection 2017.
• [73] Detergent fractionation with subsequent subtractive suppression hybridization as a tool for identifying genes coding for plasma membrane proteins.Exp Dermatol. 2009 Jun;18(6):527-35. doi: 10.1111/j.1600-0625.2008.00821.x. Epub 2009 Jan 18.
• [74] Transcriptional regulatory effects of lymphoma-associated NFKB2/lyt10 protooncogenes.Oncogene. 2000 Mar 2;19(10):1334-45. doi: 10.1038/sj.onc.1203432.
• [75] Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73.J Clin Oncol. 2005 Jun 10;23(17):3886-96. doi: 10.1200/JCO.2005.11.353. Epub 2005 May 16.
• [76] Eotaxins and CCR3 interaction regulates the Th2 environment of cutaneous T-cell lymphoma.J Invest Dermatol. 2010 Sep;130(9):2304-11. doi: 10.1038/jid.2010.128. Epub 2010 May 27.
• [77] CD164 and FCRL3 are highly expressed on CD4+CD26- T cells in Szary syndrome patients.J Invest Dermatol. 2014 Jan;134(1):229-236. doi: 10.1038/jid.2013.279. Epub 2013 Jun 21.
• [78] Skin barrier dysfunction and low antimicrobial peptide expression in cutaneous T-cell lymphoma.Clin Cancer Res. 2014 Aug 15;20(16):4339-48. doi: 10.1158/1078-0432.CCR-14-0077. Epub 2014 Jun 11.
• [79] Immunophenotyping and gene rearrangement analysis provide additional criteria to differentiate between cutaneous T-cell lymphomas and pseudo-T-cell lymphomas.Am J Pathol. 1997 Jun;150(6):1941-9.
• [80] Analysis of TGF1 and IL-10 transcriptional regulation in CTCL cells by chromatin immunoprecipitation.Methods Mol Biol. 2014;1172:329-41. doi: 10.1007/978-1-4939-0928-5_30.
• [81] Ectopic expression of cancer-testis antigens in cutaneous T-cell lymphoma patients.Clin Cancer Res. 2014 Jul 15;20(14):3799-808. doi: 10.1158/1078-0432.CCR-14-0307. Epub 2014 May 21.
• [82] Expression of intercellular adhesion molecule 3 (CDw50) on endothelial cells in cutaneous lymphomas. A comparative study between nodal and cutaneous lymphomas.Am J Dermatopathol. 1997 Aug;19(4):391-5. doi: 10.1097/00000372-199708000-00012.
• [83] MicroRNA-150 inhibits tumor invasion and metastasis by targeting the chemokine receptor CCR6, in advanced cutaneous T-cell lymphoma.Blood. 2014 Mar 6;123(10):1499-511. doi: 10.1182/blood-2013-09-527739. Epub 2014 Jan 2.
• [84] A meta-analysis of gene expression data identifies a molecular signature characteristic for tumor-stage mycosis fungoides.J Invest Dermatol. 2012 Aug;132(8):2050-9. doi: 10.1038/jid.2012.117. Epub 2012 Apr 19.
• [85] t(8;9)(p22;p24)/PCM1-JAK2 activates SOCS2 and SOCS3 via STAT5.PLoS One. 2013;8(1):e53767. doi: 10.1371/journal.pone.0053767. Epub 2013 Jan 23.
• [86] Expression of T-plastin, FoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphoma.Leuk Lymphoma. 2008 Jun;49(6):1190-201. doi: 10.1080/10428190802064917.
• [87] Szary syndrome cells overexpress syndecan-4 bearing distinct heparan sulfate moieties that suppress T-cell activation by binding DC-HIL and trapping TGF-beta on the cell surface.Blood. 2011 Mar 24;117(12):3382-90. doi: 10.1182/blood-2010-08-302034. Epub 2011 Jan 20.
• [88] BCL2 and JUNB abnormalities in primary cutaneous lymphomas.Br J Dermatol. 2004 Sep;151(3):546-56. doi: 10.1111/j.1365-2133.2004.06106.x.
• [89] Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E).Blood. 2017 Sep 21;130(12):1430-1440. doi: 10.1182/blood-2017-02-768234. Epub 2017 Jul 10.
• [90] STAT5 induces miR-21 expression in cutaneous T cell lymphoma.Oncotarget. 2016 Jul 19;7(29):45730-45744. doi: 10.18632/oncotarget.10160.
• [91] Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.Oncotarget. 2015 Aug 21;6(24):20555-69. doi: 10.18632/oncotarget.4111.
• [92] 8-methoxypsoralen reduces AKT phosphorylation, induces intrinsic and extrinsic apoptotic pathways, and suppresses cell growth of SK-N-AS neuroblastoma and SW620 metastatic colon cancer cells.J Ethnopharmacol. 2017 Jul 31;207:19-29. doi: 10.1016/j.jep.2017.06.010. Epub 2017 Jun 13.
• [93] TCR-CXCR4 signaling stabilizes cytokine mRNA transcripts via a PREX1-Rac1 pathway: implications for CTCL.Blood. 2017 Aug 24;130(8):982-994. doi: 10.1182/blood-2017-03-770982. Epub 2017 Jul 10.
• [94] Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma.Mol Cancer Ther. 2017 Oct;16(10):2304-2314. doi: 10.1158/1535-7163.MCT-17-0060. Epub 2017 Jul 20.
• [95] Zinc-dependent Deacetylase (HDAC) Inhibitors with Different Zinc Binding Groups.Curr Top Med Chem. 2019;19(3):223-241. doi: 10.2174/1568026619666190122144949.
• [96] The role of AHI1 and CDKN1C in cutaneous T-cell lymphoma progression.Exp Dermatol. 2012 Dec;21(12):964-6. doi: 10.1111/exd.12039.
• [97] BIN1 tumor suppressor regulates Fas/Fas ligand-mediated apoptosis through c-FLIP in cutaneous T-cell lymphoma.Leukemia. 2015 Jun;29(6):1402-13. doi: 10.1038/leu.2015.9. Epub 2015 Jan 12.
• [98] CD164 identifies CD4(+) T cells highly expressing genes associated with malignancy in Szary syndrome: the Szary signature genes, FCRL3, Tox, and miR-214.Arch Dermatol Res. 2017 Jan;309(1):11-19. doi: 10.1007/s00403-016-1698-8. Epub 2016 Oct 20.
• [99] Preclinical Targeting of MicroRNA-214 in Cutaneous T-Cell Lymphoma.J Invest Dermatol. 2019 Sep;139(9):1966-1974.e3. doi: 10.1016/j.jid.2019.01.033. Epub 2019 Mar 12.
• [100] Expression of human endogenous retrovirus-w including syncytin-1 in cutaneous T-cell lymphoma.PLoS One. 2013 Oct 1;8(10):e76281. doi: 10.1371/journal.pone.0076281. eCollection 2013.
• [101] STAT3/5-Dependent IL9 Overexpression Contributes to Neoplastic Cell Survival in Mycosis Fungoides.Clin Cancer Res. 2016 Jul 1;22(13):3328-39. doi: 10.1158/1078-0432.CCR-15-1784. Epub 2016 Feb 5.
• [102] A genomic and expression study of AP-1 in primary cutaneous T-cell lymphoma: evidence for dysregulated expression of JUNB and JUND in MF and SS.J Cutan Pathol. 2008 Oct;35(10):899-910. doi: 10.1111/j.1600-0560.2007.00924.x. Epub 2008 Jun 28.
• [103] Novel cell adhesion/migration pathways are predictive markers of HDAC inhibitor resistance in cutaneous T cell lymphoma. EBioMedicine. 2019 Aug;46:170-183.
• [104] cTAGE: a cutaneous T cell lymphoma associated antigen family with tumor-specific splicing.J Invest Dermatol. 2003 Jul;121(1):198-206. doi: 10.1046/j.1523-1747.2003.12318.x.
• [105] Molecular markers associated with clinical response to bexarotene therapy in cutaneous T-cell lymphoma.Acta Derm Venereol. 2011 Sep;91(5):568-73. doi: 10.2340/00015555-1114.
• [106] Association of the POT1 Germline Missense Variant p.I78T With Familial Melanoma.JAMA Dermatol. 2019 May 1;155(5):604-609. doi: 10.1001/jamadermatol.2018.3662.
• [107] Contribution of STAT3 and RAD23B in Primary Szary Cells to Histone Deacetylase Inhibitor FK228 Resistance.J Invest Dermatol. 2019 Sep;139(9):1975-1984.e2. doi: 10.1016/j.jid.2019.03.1130. Epub 2019 Mar 22.
• [108] MicroRNA-181 contributes to downregulation of SAMHD1 expression in CD4+ T-cells derived from Szary syndrome patients.Leuk Res. 2017 Jan;52:58-66. doi: 10.1016/j.leukres.2016.11.010. Epub 2016 Nov 17.
• [109] Computer-Aided Discovery of Small Molecule Inhibitors of Thymocyte Selection-Associated High Mobility Group Box Protein (TOX) as Potential Therapeutics for Cutaneous T-Cell Lymphomas.Molecules. 2019 Sep 24;24(19):3459. doi: 10.3390/molecules24193459.
• [110] miRNA?35a regulates Hut78 cell proliferation via the GATA?/TOX signaling pathway.Mol Med Rep. 2019 Mar;19(3):2361-2367. doi: 10.3892/mmr.2019.9885. Epub 2019 Jan 22.
• [111] A new protoparvovirus in human fecal samples and cutaneous T cell lymphomas (mycosis fungoides).Virology. 2016 Sep;496:299-305. doi: 10.1016/j.virol.2016.06.013. Epub 2016 Jul 7.
• [112] Association of APOA5 and APOC3 Genetic Polymorphisms With Severity of Hypertriglyceridemia in Patients With Cutaneous T-Cell Lymphoma Treated With Bexarotene.JAMA Dermatol. 2018 Dec 1;154(12):1424-1431. doi: 10.1001/jamadermatol.2018.3679.
• [113] BCL11B-Mediated Epigenetic Repression Is a Crucial Target for Histone Deacetylase Inhibitors in Cutaneous T-Cell Lymphoma.J Invest Dermatol. 2017 Jul;137(7):1523-1532. doi: 10.1016/j.jid.2017.02.980. Epub 2017 Mar 10.
• [114] CXCL17 Attenuates Imiquimod-Induced Psoriasis-like Skin Inflammation by Recruiting Myeloid-Derived Suppressor Cells and Regulatory T Cells.J Immunol. 2017 May 15;198(10):3897-3908. doi: 10.4049/jimmunol.1601607. Epub 2017 Apr 7.
• [115] Low Drosha protein expression in cutaneous T-cell lymphoma is associated with worse disease outcome.J Eur Acad Dermatol Venereol. 2019 Sep;33(9):1695-1699. doi: 10.1111/jdv.15652. Epub 2019 Jun 6.
• [116] The human Exonuclease-1 interactome and phosphorylation sites.Biochem Biophys Res Commun. 2019 Jun 30;514(3):567-573. doi: 10.1016/j.bbrc.2019.04.171. Epub 2019 May 2.
• [117] PAK1 overexpression promotes cell proliferation in cutaneous T cell lymphoma via suppression of PUMA and p21.J Dermatol Sci. 2018 Apr;90(1):60-67. doi: 10.1016/j.jdermsci.2017.11.019. Epub 2018 Jan 4.